Guided Therapeutics (GTHP) 0.0040 $GTHP Guided

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Guided Therapeutics (GTHP) 0.0040 $GTHP

Guided Therapeutics Expanding Use of the LuViva(R) Advanced Cervical Scan in Bulgaria
BusinessWire - Mon Jun 13, 7:30AM CDT
Guided Therapeutics, Inc. (OTCQB: GTHP) announced today that it has received an order and payment for a third LuViva(R) Advanced Cervical Scan and 500 single-use disposable cervical guides for Bulgaria.

Guided Therapeutics Enters into LuViva(R) Advanced Cervical Scan License Agreement for China
BusinessWire - Tue Jun 07, 7:05AM CDT
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that it has reached a licensing agreement with Shenghuo Medical, LLC, for exclusive sales and manufacturing rights of the LuViva(R) Advanced Cervical Scan for China and several additional Southeast Asian countries. Shenghuo brought Chinese investors into GTHP last year and currently owns the distribution rights to China.

Guided Therapeutics Reports Record First Quarter 2016 Results
BusinessWire - Thu May 19, 7:37AM CDT
--$262,000 of sales in 1Q 2016, a 106% increase from 2015

Guided Therapeutics Ships First LuViva(R) Advanced Cervical Scan for the Dominican Republic
BusinessWire - Wed May 11, 7:30AM CDT
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today shipment of the first LuViva(R) Advanced Cervical Scan for the Dominican Republic.

Guided Therapeutics Expands LuViva(R) Advanced Cervical Scan Distribution in Latin America
BusinessWire - Tue Feb 09, 7:30AM CST
Guided Therapeutics, Inc. (OTCQB:GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that the company continues to expand in international markets with the signing of a distributor for the Dominican Republic for the LuViva(R) Advanced Cervical Scan.

2016 U.S. Tumor Marker Testing Market
M2 - Wed Feb 03, 8:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/mzjsp8/2016_u_s_tumor) has announced the addition of the "2016 U.S. Tumor Marker Testing Market: Supplier Shares by Test, Country Volume and Sales Segment Forecasts, Innovative Technologies, Instrumentation Review, Competitive Strategies, Emerging Opportunities" report to their offering. This new report is a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines trends in the US cancer diagnostics markets; reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers and market segment; profiles leading market players and potential entrants; and suggests alternative business expansion strategies for suppliers. The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion. Company Assessments - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics/Theradiag - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Eiken Chemical - Elitech Group - Epigenomics - Enterix/Clinical Genomics - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Polymedco - PreMD - Qiagen - Quest Diagnostics - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Thermo Fisher - Tosoh For more information visit http://www.researchandmarkets.com/research/mz..._u_s_tumor
SQNM: 0.84 (-0.02), ENZ: 6.50 (-0.04), A: 46.14 (-0.44), DGX: 84.45 (-0.55), CPHD: 32.33 (-0.51), DHR: 81.29 (+0.05), HOLX: 36.57 (+0.05)

Guided Therapeutics' to Sell Five Additional LuViva(R) Advanced Cervical Scans to Nairobi County, Kenya for Cervical Cancer Screening Program
BusinessWire - Thu Jan 28, 7:30AM CST
Guided Therapeutics, Inc. (OTCQB: GTHP), a maker of a rapid and painless testing platform based on its patented biophotonic technology, today announced that Nairobi County Health Services Sector has agreed to purchase an additional five LuViva(R) Advanced Cervical Scans for use in the agency's cervical cancer screening program.

Guided Therapeutics Expects Significant Sales Growth in 2016
BusinessWire - Thu Jan 21, 8:49AM CST
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that the company expects to achieve a second consecutive quarter of record sales for the LuViva(R) Advanced Cervical Scan. The company also expects to close on an interim financing during the quarter.

Global Cancer Diagnostics 2016: Business Challenges, Emerging Technologies & Competitive Landscape
M2 - Tue Jan 19, 6:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/xd2h9v/2016_new) has announced the addition of the "2016 New Frontiers in the Global Cancer Diagnostics: Business Challenges, Emerging Technologies, Competitive Landscape" report to their offering. The report is a new study of the major business opportunities emerging in the global cancer diagnostics market during the next five years. The report examines trends in the U.S., Europe and Japan; reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers. The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide. Companies Mentioned: - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Decode Genetics - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Elitech Group - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - (20 Others) For more information visit http://www.researchandmarkets.com/research/xd2h9v/2016_new
MYGN: 32.30 (+0.33), ENZ: 6.50 (-0.04), A: 46.14 (-0.44), CPHD: 32.33 (-0.51), DHR: 81.29 (+0.05), HOLX: 36.57 (+0.05)

Guided Therapeutics Achieves Record Quarterly Revenue
BusinessWire - Tue Jan 12, 8:08AM CST
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today fourth quarter sales revenue for the LuViva(R) Advanced Cervical Scan was the highest since the launch of the product.

Global Tumor Marker Testing Market Report - Analysis, Technologies, Strategies & Forecasts 2016
M2 - Tue Jan 12, 2:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/hsj9q6/2016_analysis_of) has announced the addition of the "2016 Analysis of the Global Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Instrument and Reagent Suppliers" report to their offering. The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. Benefits of this Report: - Identifies and evaluates major business opportunities emerging in the tumor marker market during the next ten years - Examines trends in the U.S., Europe and Japan - Reviews current and emerging tumor markers - Analyzes applications of emerging diagnostic technologies - Forecasts sales of major tumor markers by country and market segment - Profiles leading market players and potential entrants Technology Review: - Assessment of monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, artificial intelligence, flow cytometry, biosensors, and their potential applications for tumor marker testing - Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy Competitive Assessments: - Extensive strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements and new products in R&D Worldwide Market Overview: - Estimated universe of laboratories performing tumor marker testing by country - Ten-year test volume and sales projections by country Business Opportunities and Strategic Recommendations: - Specific new product development opportunities with potentially significant market appeal during the next ten years - Design criteria for new products - Alternative market penetration strategies Contains 1,200 pages and 450 tables Companies Mentioned Include: - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics/Theradiag - bioMerieux - Bio-Rad - CellSearch - Elitech Group - Enterix/Clinical Genomics - Enzo Biochem - Epigenomics - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Polymedco - PreMD - Qiagen - Targeted Diagnostics & Therapeutics - Thermo Fisher - Wallac/PE - Zila For more information visit http://www.researchandmarkets.com/research/hs...nalysis_of
ENZ: 6.50 (-0.04), A: 46.14 (-0.44), DHR: 81.29 (+0.05), HOLX: 36.57 (+0.05)

US Emerging Tumor Marker Testing Market 2016: Emerging Opportunities & Growth Strategies for Instrument & Reagent Suppliers
M2 - Mon Jan 04, 3:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/43wzp4/2016_us_emerging) has announced the addition of the "US Emerging Tumor Marker Testing Market 2016: Emerging Opportunities and Growth Strategies for Instrument & Reagent Suppliers" report to their offering. This report is a comprehensive 620-page analysis of the US tumor marker testing market. The major issues pertaining to the US laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years. Mortality statistics and scientific views on the etiology of major types of cancer are included. Types of Cancer Included: - Lung - Colorectal - Breast - Prostatic - Pancreatic - Leukemia - Lymphoma - Gastrointestinal - Bladder - Liver - Ovarian - Testicular - Oral - Skin - Others. Scope of the Report: - Five-year test volume and sales forecasts over for 40 tumor marker performed in US hospitals, commercial laboratories and physician offices. - Placements and installed base of automated and semi-automated analyzers used for tumor marker testing. - Current instrumentation technologies and feature comparison of leading analyzers. - Sales and market shares of leading suppliers. - Emerging diagnostic technologies and their potential market applications. - Product development opportunities. - Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. - Business opportunities and strategic recommendations for suppliers. Companies Included: - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Decode Genetics - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Elitech Group - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - (20 Others) For more information visit http://www.researchandmarkets.com/research/43...s_emerging
MYGN: 32.30 (+0.33), ENZ: 6.50 (-0.04), A: 46.14 (-0.44), CPHD: 32.33 (-0.51), DHR: 81.29 (+0.05), HOLX: 36.57 (+0.05)

Global Pap Smear/HPV Market Report - Analysis, Technologies, Opportunities & Forecasts 2016
M2 - Thu Dec 31, 5:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/7drscd/2016_world_pap) has announced the addition of the "2016 World Pap Smear/HPV Market: Emerging Opportunities, Supplier Shares, Country Volume and Sales Segment Forecasts, Innovative Technologies, Competitive Landscape--US, Europe (France, Germany, Italy, Spain, UK), Japan" report to their offering. The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer testing market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide. This report presents a detailed analysis of the Pap Smear/HPV testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice; 5-year test volume and sales forecasts by country and market segment. The report also examines market applications of DNA probes, biochips/microarrays, monoclonal antibodies, immunoassays, IT, chromosome analysis, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks. Contains 243 pages and 7 tables Companies Mentioned: - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics/Theradiag - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Decode Genetics - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Elitech Group - Epigenomics - Enterix/Clinical Genomics - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - OncoLab - Ortho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen - Quest Diagnostics - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Thermo Fisher - Tosoh - Veridex - Wako Pure Chemicals - Wallac/PE - Zila For more information visit http://www.researchandmarkets.com/research/7d..._world_pap
MYGN: 32.30 (+0.33), A: 46.14 (-0.44), DHR: 81.29 (+0.05), SQNM: 0.84 (-0.02), ENZ: 6.50 (-0.04), DGX: 84.45 (-0.55), CPHD: 32.33 (-0.51), HOLX: 36.57 (+0.05)

European Tumor Marker Testing Market Report - Analysis, Technologies, Opportunities & Forecasts 2016
M2 - Tue Dec 29, 10:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/6qkltd/2016_future) has announced the addition of the "2016 Future Horizons and Growth Strategies in the European Tumor Marker Testing Market: Instrument and Reagents Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities" report to their offering. This unique report provides information not available from any other published source, including volume, sales, and leading supplier shares by test. This comprehensive five-country report identifies and evaluates major business opportunities emerging in the cancer diagnostics market during the next five years; examines trends in France, Germany, Italy, Spain, and the UK; reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles leading market players and potential entrants; and suggests alternative business expansion strategies for suppliers. Contains 820 pages and 320 tables Companies Mentioned: - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Decode Genetics - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Elitech Group - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - OncoLab - Ortho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen - Quest Diagnostics - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Thermo Fisher - Tosoh - Veridex - Wako Pure Chemicals - Wallac/PE - Zila For more information visit http://www.researchandmarkets.com/research/6q...016_future
MYGN: 32.30 (+0.33), A: 46.14 (-0.44), DHR: 81.29 (+0.05), SQNM: 0.84 (-0.02), ENZ: 6.50 (-0.04), DGX: 84.45 (-0.55), CPHD: 32.33 (-0.51), HOLX: 36.57 (+0.05)

Global Tumor Markers Testing Market Report: Strategic Assessments of Major Suppliers & Emerging Opportunities 2016
M2 - Tue Dec 29, 9:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/nvkchc/2016_emerging) has announced the addition of the "2016 Emerging Opportunities in the Tumor Markers Testing Market: Strategic Assessments of Major Suppliers" report to their offering. This new 80-page report from the author provides insightful analyses of major current and emerging suppliers of tumor marker diagnostic instruments and reagents. The assessments include: - Sales - Product portfolios - Distribution tactics - Technological know-how - New products in R&D - Collaborative arrangements - Business strategies Contains 80 pages Companies Mentioned: - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Decode Genetics - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Elitech Group - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - OncoLab - Ortho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen - Quest Diagnostics - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Thermo Fisher - Tosoh - Veridex - Wako Pure Chemicals - Wallac/PE - Zila For more information visit http://www.researchandmarkets.com/research/nv...6_emerging
MYGN: 32.30 (+0.33), A: 46.14 (-0.44), DHR: 81.29 (+0.05), SQNM: 0.84 (-0.02), ENZ: 6.50 (-0.04), DGX: 84.45 (-0.55), CPHD: 32.33 (-0.51), HOLX: 36.57 (+0.05)

Emerging Opportunities in the Global Respiratory Diseases Diagnostic Testing Market 2016
M2 - Wed Dec 23, 5:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/ljbdls/2016_emerging) has announced the addition of the "2016 Emerging Opportunities in the Global Respiratory Diseases Diagnostic Testing Market" report to their offering. This report presents detailed analysis of the Respiratory Disease market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on epidemiology and etiology are provided for Adenovirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV and Tuberculosis. The report provides test volume and sales forecasts by country and market segment, including: - Hospitals - Commercial/Private Labs - Physician Offices - Public Health Labs In addition to test volume and sales projections, the report presents sales and market share estimates for major suppliers of respiratory disease diagnostic products, by test and country. Also, the report: - Examines market applications of Molecular Diagnostics, - Monoclonal Antibodies, Immunoassays, IT and other emerging technologies - Reviews features and operating characteristics of major analyzers used for respiratory disease testing; - Profiles key suppliers and potential market entrants developing innovative technologies and products - Analyzes emerging opportunities, alternative market penetration strategies, market entry barriers/risks, and strategic planning issues. Companies Mentioned: - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Decode Genetics - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Elitech Group - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - (20 Others) For more information visit http://www.researchandmarkets.com/research/lj...6_emerging
ENZ: 6.50 (-0.04), A: 46.14 (-0.44), CPHD: 32.33 (-0.51), DHR: 81.29 (+0.05), HOLX: 36.57 (+0.05)

2016 New Frontiers in the US Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape
M2 - Tue Dec 15, 10:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/qj683t/2016_new) has announced the addition of the "2016 New Frontiers in the US Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape" report to their offering. "2016 New Frontiers in the US Cancer Diagnostics Market is a new study of the major business opportunities emerging in the U.S. cancer diagnostics market during the next five years. The report examines trends in the U.S. cancer diagnostics markets, reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers. Rationale The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide. Companies Mentioned - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Enterix - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - PreMD - Qiagen - Quest Diagnostics - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Thermo Fisher For more information visit http://www.researchandmarkets.com/research/qj683t/2016_new
MYGN: 32.30 (+0.33), A: 46.14 (-0.44), DHR: 81.29 (+0.05), SQNM: 0.84 (-0.02), ENZ: 6.50 (-0.04), DGX: 84.45 (-0.55), CPHD: 32.33 (-0.51), HOLX: 36.57 (+0.05)

World Cancer Diagnostics Market - 2016-2021 Future Horizons and Growth Strategies
M2 - Fri Dec 11, 9:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/pbsqpg/2016_future) has announced the addition of the "2016 Future Horizons and Growth Strategies in the World Cancer Diagnostics Market: Supplier Shares by Tumor Marker, Country Segment Forecasts, Competitive Intelligence, Opportunities" report to their offering. 2016 Future Horizons and Growth Strategies in the World Cancer Diagnostics Market is a new seven-country strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines trends in the U.S., five major European countries (France, Germany, Italy, Spain, UK) and Japan; reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles leading market players and potential entrants; and suggests alternative business expansion strategies for suppliers. Worldwide Market Overview - Estimated universe of laboratories performing cancer diagnostic testing by country. - Five-year test volume and sales projections by country. Business Opportunities and Strategic Recommendations - Specific new product development opportunities with potentially significant market appeal during the next five years. - Design criteria for new products. - Alternative market penetration strategies. - Potential market entry barriers and risks. Current and Emerging Products Review of over 200 current and emerging cancer diagnostic tests, including: - Biochemical Markers - Oncogenes - Growth Factors - Hormones - Colony Stimulating Factors - Lymphokines - Immunohisto chemical Stains, and others. - Instrumentation review analysis of major immunoassay analyzers used for cancer diagnostic testing, including their operating characteristics, features and selling prices. Technology Assessment - Assessment of monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, artificial intelligence, flow cytometry, biosensors, and other technologies and their potential applications for cancer diagnostic testing. - Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy. - Extensive listings of over 500 companies, universities and research centers developing new cancer diagnostic tests and detection technologies. Competitive Strategies - Strategic assessments ofmajor suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D. Companies Mentioned - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Cepheid - Correlogic Systems/Vermillion - Decode Genetics - Elitech Group - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - Qiagen - Quest Diagnostics - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Thermo Fisher - Tosoh For more information visit http://www.researchandmarkets.com/research/pb...016_future
MYGN: 32.30 (+0.33), A: 46.14 (-0.44), DHR: 81.29 (+0.05), SQNM: 0.84 (-0.02), ENZ: 6.50 (-0.04), DGX: 84.45 (-0.55), CPHD: 32.33 (-0.51), HOLX: 36.57 (+0.05)

Innovative Therapies, Diagnostics, and Events Propel These Hot Promising Small Caps
ACCESSWIRE - Wed Dec 09, 6:50AM CST
SALT LAKE CITY, UT / ACCESSWIRE / December 9, 2015 / An array of small biotech companies are making waves in the industry by presenting new, alternative medicines and therapies that perform better than their predecessors, while often available at a lower cost.
AVXL: 7.46 (+0.60)

Guided Therapeutics ships first 10,000 LuViva advanced cervical scan disposables to Turkey
M2 - Fri Dec 04, 6:21AM CST
Painless testing platform company Guided Therapeutics (OTCBB:GTHP) declared on Thursday that it has delivered the first 10,000 LuViva Advanced Cervical Scan single-patient-use Cervical Guide disposables under the USD14m Turkish Ministry of Health (MOH) agreement.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Madrigal Pharmaceuticals Faces Legal Scrutiny Over Data

Updated Category News Views 152

Legal Storm Brews for Madrigal Pharmaceuticals Watch out, here comes another storm for Madrigal Pharmaceuticals, folks. This ain't no small drizzle either; it's a full-on legal monsoon, and it's soaked straight through the walls of their executive suite. We're talking a whistleblower sending alarm bells ringing about data fudging and some dodgy boardroom maneuvers—as if...

Continue Reading
Floating Solar Gets a Serious Test in Central New York

Updated Category News Views 120

A flooded quarry pit outside Cortlandville is getting a second career, and that is more interesting than another solar announcement draped across empty acreage. Third Pillar Power has started construction on Crown City Solar at Suit-Kote Corporation's active Polkville Crushed Stone Facility, pairing a working mine, asphalt plant, and storage terminal with what the...

Continue Reading
Xailient Tops NIST for Real-World AI Face Recognition

Updated Category News Views 87

In a world where bigger ain't always better, Xailient's latest triumph at NIST's face recognition test has set them apart. On November 17, 2026, the U.S. National Institute of Standards and Technology (NIST) crowned Xailient as the leader in face recognition accuracy for on-device AI, leaving 105 others in the dust. This ain't your run-of-the-mill achievement—it shows...

Continue Reading
IIT Madras Maps 100 Brains in a Serious Science Bet

Updated Category News Views 14

A human brain turned into a navigable cellular map is not a flashy launch-day trinket. It is painstaking infrastructure, the kind that can sit quietly for years before researchers figure out what it truly unlocks. That is why the Sudha Gopalakrishnan Brain Centre mission at IIT Madras deserves a serious look rather than the usual chest-thumping over a big scientific...

Continue Reading
ZAKSIMLAB Tests Kombucha and Salmon Snack Pairing in Cafes

Updated Category News Views 127

A fish-based chip beside a fizzy tea mix is an odd little commercial wager, and that is exactly why ZAKSIMLAB's latest move deserves a look. The Seoul food brand launched Salmon Crunch Protein Chips in September, then put the snack next to its powdered kombucha at the 2026 Cafe & Bakery Fair Season 2. This is not a grand earnings story; no sales, pricing, store-count, or...

Continue Reading
Toledo Crosswalk Death Lawsuit Raises Hard Questions

Updated Category News Views 249

A painted crosswalk is supposed to mean something, and that is the grim center of the lawsuit filed over Judy Tanner’s death in Toledo. Tanner, 20, was walking home from work on September 10, 2026, when she was struck and killed while crossing the street. Her estate is now suing, alleging that the 31-year-old driver failed to yield as Tanner legally used the crosswalk....

Continue Reading
Holiday Grease Advice Shows Utility Work Up Close Today

Updated Category News Views 117

Butter and pan drippings are mundane right until they become a backed-up kitchen line on a crowded holiday afternoon. New Jersey American Water's Nov. 17, 2026 reminder is not glamorous utility news, and frankly it is not trying to be. It is a practical warning: fats, oils and grease can cool, harden and accumulate in household pipes and farther along the wastewater...

Continue Reading
USFM's Disko Deal Waits on Greenland Until March 2027

Updated Category News Views 184

A missing Greenland signature has turned USFM’s grand Disko plan into a calendar problem. Nothing more dramatic has been disclosed, but nothing less consequential should be assumed either. March 31 replaces a deadline that already failed USFM executed its share purchase agreement with 80 Mile PLC and Disko Exploration Limited on May 8, 2026. The proposed bargain is...

Continue Reading
Texas Community Bancshares Adds a Special Dividend

Updated Category News Views 109

Nine cents is the whole message—for the moment Texas Community Bancshares has put a little extra cash on the table, declaring a regular quarterly dividend of $0.06 per common share and a special cash dividend of $0.03 per share. Together, holders get $0.09 per share, payable on or about December 15, 2026, provided they are shareholders of record when business closes on...

Continue Reading
Trilith Holiday Tour Blends Film Access and Giving

Updated Category News Views 53

Snow machines, trolley rides, and a mental-health subsidy are sharing the same stage in Fayetteville this holiday season. That is an unusual mix, but it fits Trilith Foundation’s stated mission better than another generic lights-and-cocoa event ever could. From Nov. 21 through Dec. 31, the Foundation is turning its guided Trilith Studios tour into a seasonal experience...

Continue Reading

Top 5 Most Recently Viewed Articles

Kos Biotechnology Closes Record-Breaking $123M Fund

Updated Category News Views 80

Unprecedented Funding for Life Sciences When you hear about a $123 million fund popping up from nowhere, you stop and take notice. Kos Biotechnology Partners, a name that's bursting onto the scene with a hefty global life sciences fund, isn't messing around. Got their roots sinking into both New York and the ancient soil of Athens—this isn't just some flash-in-the-pan...

Continue Reading
Lyric Advances Battery Technology with Innovative Equipment

Updated Category News Views 149

Lyric's Innovative Contributions in Battery Technology Recently, Lyric successfully shipped its first solid-state battery front-end equipment to a customer, marking a significant milestone in their ongoing advancements in battery production technology. This achievement is a testament to Lyric's extensive experience and deep expertise in the field of solid-state batteries,...

Continue Reading
Danish Stock Market Update: Modest Decline and Notable Movers

Updated Category News Views 226

Danish Stock Market Sees Modest Decline The recent trading session in Denmark concluded with a slight downturn, marking a challenging day for investors as the OMX Copenhagen 20 index closed lower. The end of trading saw the index experiencing a reduction of 0.23%, setting a new six-month low. Such fluctuations can often reflect broader economic sentiments and provide...

Continue Reading
LiTHOS Group Advances Lithium Extraction with New Patent

Updated Category News Views 275

LiTHOS Group Innovates Lithium Extraction Techniques LiTHOS Group Ltd. (CBOE CA: LITS), a leader in sustainable lithium brine extraction, has achieved a significant milestone by securing a U.S. patent. The United States Patent and Trademark Office (USPTO) has allowed their patent for the "Electro-Pressure Membrane Method for Recovery and Concentration of Lithium from...

Continue Reading
Karbach Brewing: Your Ideal Venue for Memorable Celebrations

Updated Category News Views 378

Karbach Brewing: A New Venue for Unforgettable Corporate Events As the festive season approaches, businesses in Houston are searching for the ideal place to host their corporate holiday celebrations. Enter Karbach Brewing, a name that is rapidly becoming synonymous with memorable experiences. This brewery is not just about beer; it offers companies a distinctive setting...

Continue Reading